At a median follow-up of 3.5 years, rituximab plus lenalidomide demonstrated durable CR/CRu and prolonged PFS vs rituximab alone in previously untreated in follicular lymphoma.
Fixed-dose pembrolizumab achieved an ORR of 69% in heavily pretreated patients with R/R cHL with most responses ongoing for at least 6 months.
Ibrutinib demonstrated an ORR of 48% across patients with 3 different subtypes of relapsed/refractory marginal zone lymphoma.
Maintenance rituximab after ASCT prolongs EFS, PFS, and OS for younger patients with mantle cell lymphoma vs observation only.
Rituximab biosimilar GP2013 plus CVP demonstrated equivalent ORR and comparable safety profile vs rituximab plus CVP as initial therapy for advanced follicular lymphoma.
Brentuximab vedotin provided durable objective response and significantly improved CR rates and PFS in patients with CD30+ CTCL.
In this study, median PFS with ibrutinib was similar in the clinical trial and real-world settings, although more patients discontinued for treatment-related adverse events in the real-world setting.
Median PFS is improved with FCR vs BR in fit younger patients with CLL, although BR remains an option for fit elderly patients with a lower risk of second primary malignancies.
Phase III study showed similar EFS and OS with both regimens and increased rate of adverse events with DA-EPOCH-R in DLBCL.
Lenalidomide maintenance therapy in elderly patients with DLBCL significantly improved PFS compared with placebo.
Obinutuzumab-based therapy reduced the risk of progression or death by 34% compared with rituximab-based therapy in patients with untreated follicular lymphoma.
Venetoclax associated with high response rates and durable responses in patients with CLL who progressed on ibrutinib, idelalisib, or both.
In this expert analysis, John M. Burke, MD, and Jeff P. Sharman, MD, review key data from the most clinically relevant studies on the management of lymphomas and CLL presented at the Hematology 2016 annual meeting.
Interim analysis reported significantly higher ORR and markedly greater CR with KTE-C19 vs historical rates in chemorefractory patients with DLBCL.
In this downloadable slideset, John M. Burke, MD, and Jeff P. Sharman, MD, highlight key data presented at Hematology 2016.